---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-009245"
form_type: "8-K"
ticker: null
cik: "0000876378"
company_name: "ASENSUS SURGICAL, INC."
filed_at: "2024-03-25T23:59:59+00:00"
generated_at: "2026-06-04T08:53:40.224451+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Asensus Surgical reports Q4 revenue $5.4M; going concern; cash only through early June 2024

## Summary
- Q4 2023 revenue $5.4M vs $2.5M YoY; net loss $17.2M ($0.07/share) vs $17.9M ($0.08).
- Full year 2023 revenue $8.6M; 8 Senhance programs initiated; 3,550+ procedures (+13% YoY).
- Cash and equivalents $21.1M at Dec 31, 2023; expects cash to sustain operations only until early June 2024.
- Company will file 10-K with going concern qualification from independent auditor.
- LUNA system development on track: design freeze expected H2 2024; Flex agreement for manufacturing.

## SEC filing metadata
- accession: 0001437749-24-009245
- form_type: 8-K
- cik: 0000876378
- company_name: ASENSUS SURGICAL, INC.
- filed_at: 2024-03-25T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/876378/000143774924009245/0001437749-24-009245-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/876378/000143774924009245/asxc20240321_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-009245
- JSON: https://secwatch.observer/filing/0001437749-24-009245.json
- Plain text: https://secwatch.observer/filing/0001437749-24-009245.txt

## Key facts
- Earnings Releases
  ASENSUS SURGICAL, INC. reported the fourth quarter and year ended December 31, 2023 results: revenue $8.6 million.
  - Period: the fourth quarter and year ended December 31, 2023
  - Revenue: $8.6 million
  - Result: reported results
  source text: growth of over 13% compared to 2022 ● In 2023, 8 Senhance Surgical Programs were initiated, which is in line with guidance of 8-10 systems ● Full year 2023 revenue of $8.6 million ● The Company had cash, cash equivalents and short-term investments, excluding restricted cash, of approximately $21.1 million at December 31, 2023 Fourth Quarter Highlights ●
  evidence_url: https://www.sec.gov/Archives/edgar/data/876378/000143774924009245/0001437749-24-009245-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.